Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.69 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.53 |
| ▸ | F10 | P00742 | 2/20 | 0.52 |
| ▸ | PYGL | P06737 | 9/20 | 0.52 |
| ▸ | PYGM | P11217 | 6/20 | 0.52 |
| ▸ | F7 | P08709 | 1/20 | 0.51 |
| ▸ | F3 | P13726 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603066 | 1.00 | SMYD3 (0.69) | SMYD3MLLT1F10PYGLPYGM | |
| SCHEMBL3603062 | 1.00 | SMYD3 (0.69) | SMYD3MLLT1F10PYGLPYGM | |
| SCHEMBL30578672 | 0.93 | SMYD3 (0.76) | SMYD3MLLT1PYGLPYGMF7 | |
| SCHEMBL3603913 | 0.90 | ALOX15 (0.56) | SMYD3MLLT1F10PYGLPYGM | |
| SCHEMBL3603019 | 0.90 | ALOX15 (0.56) | SMYD3MLLT1F10PYGLPYGM | |
| SCHEMBL3603024 | 0.90 | ALOX15 (0.56) | SMYD3MLLT1F10PYGLPYGM | |
| SCHEMBL3610530 | 0.85 | MLLT1 (0.73) | SMYD3MLLT1PYGLPYGMMEN1 | |
| SCHEMBL3605634 | 0.85 | GHSR (0.55) | SMYD3MLLT1PYGLPYGMRXFP1 | |
| SCHEMBL3610534 | 0.85 | MLLT1 (0.73) | SMYD3MLLT1PYGLPYGMMEN1 | |
| SCHEMBL3607418 | 0.85 | MLLT1 (0.53) | SMYD3MLLT1PYGLPYGMHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | SMYD3 811/4885MLLT1 2603/4885F10 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.